Lupin Of India Sued In U.S. By Novo Of Denmark Over Diabetes Generic
This article was originally published in PharmAsia News
Executive Summary
India's Lupin has been sued by Novo Nordisk over Lupin's effort to market a generic for treating diabetes in the United States